MHRA is now consulting on proposals to ‘streamline’ clinical trial approvals and boost transparency
The UK’s medicines regulator has set out plans to “streamline” the approvals process for clinical trials in a bid to make the country “the best place to research and develop safe and innovative medicines” post Brexit.
The plans, which went out for consultation on 17 January, include proposals to merge the regulatory and research ethics approval process, boost research transparency and change the reporting requirements of safety risks for trials.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.